Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Nivolumab in Combination with Ipilimumab in Patients with Advanced Neuroendocrine Tumors

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of nivolumab plus ipilimumab in patients with advanced neuroendocrine tumors, including pancreatic neuroendocrine tumors (pNETs).

General Information

NCT#: NCT03420521
Study ID: J17156
Trial Phase: Phase II

Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Ipilimumab, Nivolumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search